The Value Composite Two of Cymabay Therapeutics, Inc. (NasdaqCM:CBAY) is 95. The VC2 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, price to earnings and shareholder yield. Similarly, the Value Composite One (VC1) is a method that investors use to determine a company’s value. The VC1 of Cymabay Therapeutics, Inc. (NasdaqCM:CBAY) is 94. A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company. The VC1 is calculated using the same metrics as VC2, but without taking into consideration shareholder yield.
Investors may be taking a look at certain business aspects when attempting to research a stock. Investors often look to see if the stock’s specific industry is on the rise. There may be a greater chance of success when investing in an industry that is rapidly growing. Investors may then want to see how the company stacks up within the industry. Many investors will look for stocks that are proven industry leaders. Industry leaders have the ability to influence pricing and not necessarily be susceptible to what other companies are doing around them. Investors may also be taking note of how a company invests in research and development. Companies that are focused on the future may have a competitive advantage over those who are too focused on the near-term.
At the time of writing, Cymabay Therapeutics, Inc. (NasdaqCM:CBAY) has a Piotroski F-Score of 4. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.
Watching some historical volatility numbers on shares of Cymabay Therapeutics, Inc. (NasdaqCM:CBAY), we can see that the 12 month volatility is presently 85.044900. The 6 month volatility is 61.104700, and the 3 month is spotted at 58.304500. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.
Shifting gears, we can see that Cymabay Therapeutics, Inc. (NasdaqCM:CBAY) has a Q.i. Value of 74.00000. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be.
Cymabay Therapeutics, Inc. (NasdaqCM:CBAY) has a current MF Rank of 14390. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks. Cymabay Therapeutics, Inc. has a current ERP5 Rank of 15485. The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.
Cymabay Therapeutics, Inc. has an M-score Beneish of -999.000000. This M-score model was developed by Messod Beneish in order to detect manipulation of financial statements. The score uses a combination of eight different variables. The specifics of the variables and formula can be found in the Beneish paper “The Detection of Earnings Manipulation”.
Investors may be interested in viewing the Gross Margin score on shares of Cymabay Therapeutics, Inc. (NasdaqCM:CBAY). The name currently has a score of 50.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative.
We can now take a quick look at some historical stock price index data. Cymabay Therapeutics, Inc. (NasdaqCM:CBAY) presently has a 10 month price index of 3.70526. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 3.36842, the 24 month is 2.50534, and the 36 month is 0.94624. Narrowing in a bit closer, the 5 month price index is 1.70460, the 3 month is 1.52381, and the 1 month is currently 1.11041.